{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:03:40Z","timestamp":1790251420924,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.antiviral.2018.10.013","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T12:28:15Z","timestamp":1539692895000},"page":"48-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["2\u2032-Fluoro-2\u2032-deoxycytidine is a broad-spectrum inhibitor of bunyaviruses in vitro and in phleboviral disease mouse models"],"prefix":"10.1016","volume":"160","author":[{"given":"Donald F.","family":"Smee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kie-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonna","family":"Westover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian B.","family":"Gowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.10.013_bib1","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1128\/AAC.48.4.1422-1425.2004","article-title":"2'-fluoro-2'-deoxycytidine inhibits Borna disease virus replication and spread","volume":"48","author":"Bajramovic","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.013_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1743-422X-5-25","article-title":"La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeys","volume":"5","author":"Bennett","year":"2008","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2018.10.013_bib3","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1128\/JVI.75.3.1371-1377.2001","article-title":"Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs","volume":"75","author":"Bouloy","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.10.013_bib4","first-page":"1244","article-title":"Bunyaviridae","volume":"vol. 2","author":"Elliott","year":"2013"},{"key":"10.1016\/j.antiviral.2018.10.013_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/v8080223","article-title":"What do we know about how hantaviruses interact with their different hosts?","volume":"8","author":"Ermonval","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.10.013_bib6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.10.013_bib7","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1128\/AAC.35.7.1448","article-title":"Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A\/WSN virus","volume":"35","author":"Gilbert","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.013_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01942-16","article-title":"Modeling severe fever with thrombocytopenia syndrome virus infection in golden syrian hamsters: importance of STAT2 in preventing disease and effective treatment with favipiravir","volume":"91","author":"Gowen","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.10.013_bib9","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/AAC.00356-07","article-title":"In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections","volume":"51","author":"Gowen","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.013_bib10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/infdis\/153.3.489","article-title":"Ribavirin therapy for Hantaan virus infection in suckling mice","volume":"153","author":"Huggins","year":"1986","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.10.013_bib11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.antiviral.2011.09.001","article-title":"In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections","volume":"92","author":"Kumaki","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.10.013_bib12","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s00705-018-3843-5","article-title":"Taxonomy of the family Arenaviridae and the order Bunyavirales: update 2018","volume":"163","author":"Maes","year":"2018","journal-title":"Arch. Virol."},{"key":"10.1016\/j.antiviral.2018.10.013_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fmicb.2017.00104","article-title":"Animal models of emerging tick-borne phleboviruses: determining target cells in a lethal model of SFTSV infection","volume":"8","author":"Matsuno","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.antiviral.2018.10.013_bib14","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1086\/425007","article-title":"Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America","volume":"39","author":"Mertz","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.10.013_bib15","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"key":"10.1016\/j.antiviral.2018.10.013_bib16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/019262339902700601","article-title":"An evaluation of the toxicities of 2'-fluorouridine and 2'-fluorocytidine-HCl in F344 rats and woodchucks (Marmota monax)","volume":"27","author":"Richardson","year":"1999","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.antiviral.2018.10.013_bib17","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1021\/tx020014d","article-title":"Quantification of 2'-fluoro-2'-deoxyuridine and 2'-fluoro-2'-deoxycytidine in DNA and RNA isolated from rats and woodchucks using LC\/MS\/MS","volume":"15","author":"Richardson","year":"2002","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.antiviral.2018.10.013_bib18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.antiviral.2008.09.007","article-title":"Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea","volume":"81","author":"Rusnak","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.10.013_bib19","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1128\/AAC.00886-13","article-title":"Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome","volume":"57","author":"Safronetz","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.013_bib20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.01.016","article-title":"Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment","volume":"104","author":"Scharton","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.10.013_bib21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1128\/AAC.32.3.331","article-title":"In vitro and in vivo Phlebovirus inhibition by ribavirin","volume":"32","author":"Sidwell","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.013_bib22","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2018.10.013_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/095632020101200602","article-title":"Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro","volume":"12","author":"Smee","year":"2001","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.10.013_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jviromet.2017.03.012","article-title":"Evaluation of cell viability dyes in antiviral assays with RNA viruses that exhibit different cytopathogenic properties","volume":"246","author":"Smee","year":"2017","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.antiviral.2018.10.013_bib25","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/AAC.48.2.651-654.2004","article-title":"Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2'-deoxy-2'-fluorocytidine","volume":"48","author":"Stuyver","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.013_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00061-15","article-title":"Efficacy of T-705 (favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus","volume":"1","author":"Tani","year":"2016","journal-title":"mSphere"},{"key":"10.1016\/j.antiviral.2018.10.013_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2017.10.008","article-title":"Identification of 2'-deoxy-2'-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus","volume":"147","author":"Welch","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.10.013_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.virol.2017.08.004","article-title":"Heartland virus infection in hamsters deficient in type I interferon signaling: protracted disease course ameliorated by favipiravir","volume":"511","author":"Westover","year":"2017","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.10.013_bib29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0167-4781(85)90053-3","article-title":"The effect of 2'-fluoro-2'-deoxycytidine on herpes virus growth","volume":"824","author":"Wohlrab","year":"1985","journal-title":"Biochim. Biophys. Acta"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218304108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218304108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:27:47Z","timestamp":1759062467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218304108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":29,"alternative-id":["S0166354218304108"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.10.013","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2\u2032-Fluoro-2\u2032-deoxycytidine is a broad-spectrum inhibitor of bunyaviruses in vitro and in phleboviral disease mouse models","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}